Vapors, gases, dusts and fumes at work and chronic obstructive pulmonary disease/bronchitis: a systematic review and meta-analyses Authors: Victoria H. Arrandale, Yizhi Zhang, Wendy Lou, Andrea C. Tricco, Ambrose Lau, Ani Orchanian-Cheff, Paul K. Henneberger, Susan M. Tarlo Published: 2026 ABSTRACT BackgroundChronic obstructive pulmonary disease (COPD) is the third leading cause of death after cardiovascular disease and stroke. A 2019 American Thoracic Society (ATS) statement estimated that 13–15% of all COPD is attributable to occupational exposures.Research questionThis study reports on a systematic review with meta-analysis (PROSPERO 2022 CRD42022302451) that was undertaken to characterize jobs and work exposures associated with an increased risk of developing COPD.MethodsFive databases were searched (MEDLINE, Embase, CINAHL, Cochrane Systematic reviews, Register of Controlled Trials) from inception until February 26, 2025. Studies published in English or Chinese that studied workers (or workplace exposures) in relation to COPD, chronic bronchitis (CB) or emphysema and reported on a minimum of 15 exposed cases, with a comparison group, were included. The National Heart, Blood, and Lung Institute (NHLBI) Study Quality Assessment Tool was used. All reported estimates (e.g., RR, OR, HR) were extracted. Random effects models were used to estimate meta effect estimates (mEE) with 95% confidence intervals. Stratified models were constructed by study design, smoking, and sex, where possible.ResultsAfter de-duplication, 9115 citations were screened. Following full-text review 257 studies met the inclusion criteria. Most were cross-sectional (71%) and conducted in Europe or North America (68%). Most were fair quality (72%) with only 5.8% assessed as good quality. Results showed a consistent relationship between workplace exposure to vapours, gases, dusts or fumes (VGDF) for spirometry-defined COPD (mEE 1.51; 95% CI 1.31–1.73; n = 20 studies), self-reported COPD (mEE 1.48; 95% CI 1.23–1.77; n = 14) and chronic bronchitis (mEE 1.83; 95% CI 1.51–2.21; n = 29). This relationship was slightly stronger in non-smokers and was weaker among women.InterpretationThere was a consistent relationship of workplace exposures with both CB and COPD. The effect of occupational exposures on COPD outcomes appears to be at least additive with smoking.Clinical trial registrationThe project was registered with PROSPERO, the International Prospective Register of Systematic Reviews (PROSPERO 2022 CRD42022302451). Date of registration: 5th April 2022.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12995-026-00515-7. Introduction Chronic obstructive pulmonary disease (COPD) is the third leading cause of death after cardiovascular disease and stroke. COPD is a common chronic condition that has been defined on the basis of fixed (irreversible) airflow limitation, demonstrated on spirometry [1]. The Global Obstructive Lung Disease (GOLD) [2, 3] criteria have taken a cut-off of a post-bronchodilator FEV1/FVC ratio of 70% or less for diagnosis of COPD, although there has been disagreement in the medical literature on taking a fixed cut-off for diagnosis, due to the normal decline in this ratio with increasing age. Therefore, some experts have advised use of the lower limit of the reference value of FEV1/FVC ratio, which includes consideration of age, sex, and height, and also ideally, should be based on local reference values. In addition, severity of COPD using the GOLD criteria 2017 has included consideration of symptoms and exacerbations [4]. It has also been suggested that additional pulmonary function tests, symptoms and radiographic changes may be helpful in the diagnosis [5]. COPD as defined above is not a single disease. The same pulmonary function findings on spirometry may occur in bronchiectasis, bronchiolitis and in some patients with long-standing or severe asthma in addition to those with chronic bronchitis and emphysema [6]. In addition, these findings may be a normal variant in patients with lung dysanaptic growth, i.e., non-proportional growth of airways and lungs that results in relatively small airways compared with lung volumes [7]. Therefore, a clinical diagnosis requires consideration of additional factors such as the patient’s history of symptoms, occupational and environmental exposures, past medical history, medications, physical examination, and radiographic findings to exclude other explanations of the spirometry findings. The prevalence of COPD in Canadian adults aged 40 and older is 11.2%, using the cut-off criteria of the lower limit of normal (LLN) FEV1/FVC ratio post-bronchodilator, and 16.2% using the fixed cut-off ratio of 70% [8]. In the USA Liu et al. report that in 2021, 6.0% (95% CI 5.9–6.2%; age standardized) of adults in a population-based sample self-reported a doctor diagnosis of COPD [9]. Cadham et al. (2024) used spirometry data from 2011 to 2012 NHANES data and report that 14.1% (95% CI 12.3–16.0%) of adults (20–79 years) had COPD defined as FEV1/FVC < 0.7 [10]. The most common identified cause of COPD is tobacco smoking although other causes such as air pollution and occupational exposures play a significant role in a subset of COPD patients, which may increase in relative importance as smoking rates fall [11]. Several previous studies have concluded that occupational exposures can cause and/or contribute to COPD [12–14]. This has been recognised in cohorts of workers exposed to inorganic dusts, such as miners exposed to coal and silica dust, and has also been recognised with exposure to organic dusts in woodworkers and farmers. In addition, it has been recognised that more general exposure to vapors, gases, dusts and fumes (VGDF) individually or in combination, and with or without cigarette smoking, is also a predisposing factor for COPD [13], and may be associated with more severe COPD [15]. Epidemiologic studies reviewed in official statements from the American Thoracic Society (ATS) in 2003 and 2019 have shown that occupational exposures to VGDF contribute to approximately 13–15% of all COPD [16, 17]. Previous systematic reviews and meta-analyses have been performed to address various aspects of COPD and effects of occupational exposures [18–27]. Eight of these were also reviewed in a summary paper [28]. These reviews have confirmed a significant contribution from workplace exposures to the development of COPD with and without a personal smoking history [28]. Sadhra et al. (2017) focused on papers published 1980–2015 and reported that a job exposure matrix (JEM) based on expert consensus provided a greater exposure risk than a workplace-based JEM risk [18]. The risk was greater for self-reported VGDF exposure (OR 1.91, 95%CI 1.72–2.13) compared to JEM assessed exposure (OR 1.10; 95%CI 1.06–1.24) [18]. They reported the highest risk from dusts (OR 1.37, 95%CI 1.30–1.45), with a higher effect for biological dusts (OR 1.33, 95%CI 1.17–1.51) rather than mineral dusts (OR 1.07, 95%CI 1.05–1.09). However, most of these reviews have not reported the effects of possible interaction of exposure to VGDF with other risk factors for COPD besides tobacco smoking. In addition, there is little known regarding subsets of workers at increased risk of COPD from VGDF alone or with a smoking history. The latency period after exposure and possible progression after removal from exposure have also not been well characterized. This paper reports on results from a recent systematic review to quantify the relationship of VGDF with COPD, chronic bronchitis (CB) and emphysema. Methodology The protocol for this systematic review was developed by the research team, guided by the Cochrane Handbook and registered with PROSPERO, the International Prospective Register of Systematic Reviews (PROSPERO 2022 CRD42022302451) [29]. Results are reported using PRISMA guidelines (Supplementary Table S2) [30]. This review did not require institutional research ethics review since it was a review of previous completed studies. A comprehensive search strategy was developed by an experienced librarian (AOC) in collaboration with the research team to identify studies on occupational exposure leading to COPD. The search was peer reviewed by another librarian using the PRESS checklist [31]. The following databases were searched from inception on April 26, 2022, and updated on September 6, 2023 and again on February 26, 2025: Ovid MEDLINE ALL, EBM Reviews – Cochrane Database of Systematic Reviews (Ovid), EBM Reviews – Cochrane Central Register of Controlled Trials (Ovid), Embase (Ovid), and CINAHL Complete/Ultimate (EBSCOhost). Supplemental Table S2 presents all executed search strategies. Difficult to locate and unpublished material (i.e., grey literature) was also examined, including websites of Canadian provincial workers’ compensation boards, and government agencies equivalent to Ministries of Labour, as well as several international organizations and corresponding websites (summarized in Supplemental Table S3). Inclusion criteria were: Full paper or report.Written in the English or Chinese language, to align with linguistic knowledge of the study team.Studies of workers or workplace exposures.Outcome is COPD, chronic bronchitis or emphysema, meeting outcome definitions.examined VGDF overall, specific VGDF exposures (e.g., dusts, welding), specific occupations as a proxy for exposure, or specific industries as a proxy for exposure.Reported on a minimum of 15 exposed cases, with a comparison group to allow more robust statistical comparisons. Full paper or report. Full paper or report. Written in the English or Chinese language, to align with linguistic knowledge of the study team. Written in the English or Chinese language, to align with linguistic knowledge of the study team. Studies of workers or workplace exposures. Studies of workers or workplace exposures. Outcome is COPD, chronic bronchitis or emphysema, meeting outcome definitions. Outcome is COPD, chronic bronchitis or emphysema, meeting outcome definitions. examined VGDF overall, specific VGDF exposures (e.g., dusts, welding), specific occupations as a proxy for exposure, or specific industries as a proxy for exposure. examined VGDF overall, specific VGDF exposures (e.g., dusts, welding), specific occupations as a proxy for exposure, or specific industries as a proxy for exposure. Reported on a minimum of 15 exposed cases, with a comparison group to allow more robust statistical comparisons. Reported on a minimum of 15 exposed cases, with a comparison group to allow more robust statistical comparisons. No restrictions regarding study design, exposure metric, country, patient age, race, gender, or publication date were placed on the initial search. The five acceptable outcome definitions are shown in Box 1. 1. COPD by diagnostic testing Post bronchodilator lung function where FEV1/FVC ratio is < an accepted limit (LLN, or 0.7) 2. COPD by self report A self-reported physician diagnosis of COPD on questionnaire/interview OR physician diagnosis as part of study protocol3. Chronic BronchitisStudies that used the accepted ATS/ERS definition (cough and phlegm for 3 months a year for at least 2 years) OR a self-reported physician diagnosis of chronic bronchitis on questionnaire/ interview OR physician diagnosis as part of study protocol4. EmphysemaStudies that used CT or radiographic or pathology evidence to identify cases of emphysema OR a self-reported physician diagnosis of emphysema on questionnaire/interview OR physician diagnosis as part of study protocol5. COPD, CB or Emphysema by administrative dataCases identified through administrative data as Other Chronic Obstructive Pulmonary Disease (using either code 496 in ICD-9 or J44 in ICD-10) OR Emphysema (using either code 492 in ICD-9 or J43 in ICD-10) OR Chronic Bronchitis (either code 491 in ICD-9 or J41 or J42 in ICD-10.) Acute Bronchitis was excluded. 1. COPD by diagnostic testing Post bronchodilator lung function where FEV1/FVC ratio is < an accepted limit (LLN, or 0.7) 2. COPD by self report A self-reported physician diagnosis of COPD on questionnaire/interview OR physician diagnosis as part of study protocol3. Chronic BronchitisStudies that used the accepted ATS/ERS definition (cough and phlegm for 3 months a year for at least 2 years) OR a self-reported physician diagnosis of chronic bronchitis on questionnaire/ interview OR physician diagnosis as part of study protocol4. EmphysemaStudies that used CT or radiographic or pathology evidence to identify cases of emphysema OR a self-reported physician diagnosis of emphysema on questionnaire/interview OR physician diagnosis as part of study protocol5. COPD, CB or Emphysema by administrative dataCases identified through administrative data as Other Chronic Obstructive Pulmonary Disease (using either code 496 in ICD-9 or J44 in ICD-10) OR Emphysema (using either code 492 in ICD-9 or J43 in ICD-10) OR Chronic Bronchitis (either code 491 in ICD-9 or J41 or J42 in ICD-10.) Acute Bronchitis was excluded. The review was managed using Covidence [32]. Both the title and abstract screening and full text review tools were pilot tested repeatedly, to improve agreement between reviewers. Title and abstract review as well as the full text reviews were conducted by two people independently. Conflicts were resolved between the two participating reviewers or, where needed, a third reviewer. The data extraction template was developed with input from the entire research team using the Cochrane handbook as a guide [33]. Due to time and resource limitations, initially data extraction was performed in duplicate to ensure consistency (approximately 40% of the included papers); the remainder of the papers were extracted by a single, experienced team member. Studies were assessed in duplicate using the National Heart, Blood, and Lung Institute (NHLBI) Study Quality Assessment Tool [34]. Studies were combined via meta-analysis only where they reported on the same outcome and the same exposure metric. Additional models were developed separately for cross-sectional and cohort studies when there were 3 or more papers with the same study design. Reported effect estimates (e.g., RR, OR, HR) were combined for the purposes of modeling; the majority of effect estimates reported in included studies were ORs. Meta effect estimates (mEE) with 95% confidence intervals (95%CI) were estimated using random effects models (package metafor [35]) in R [36] with individual studies as the random effects. Heterogeneity was assessed using Higgins I [2] and interpreted using a modification of the Cochrane guidance (< 30%: marginal, 30–60% moderate; 60–90% substantial, and > 90% as considerable) [37]. Forest plots were examined to visually assess the heterogeneity and to present meta effect estimates relative to individual study results. Where more than ten studies were available for meta-analysis, funnel plots were examined to assess the potential for publication bias [38]. Following initial model construction, a leave-one-out analysis was completed as a sensitivity analysis to ensure results were robust to the removal of individual studies. Where multiple estimates from a single paper could contribute to a single model, the estimate based on the largest number of exposed cases was selected. Where multiple papers from a single study or dataset could contribute to a single model (same outcome group and same exposure metric), the estimate reported for the exposure circumstance that best matched the model was selected, based on the exposure definition or descriptive information. Models examining specific exposures, occupations and industries were constructed where a sufficient number (n ≥ 3) of studies were available. Sensitivity analyses were conducted to examine results stratified by study design and assessed study quality; changes to the mEE and heterogeneity were of particular interest. Given the importance of smoking in the developing of COPD, models were limited to estimates that were adjusted for smoking. Where sufficient numbers of studies were present, models were constructed stratified by smoking status and sex. Among studies that considered exposure as semi-quantitative categories (e.g., low, medium, high, with or without numeric cut points) models were constructed to examine the risk among the highest exposure level or longest exposure duration group, as compared to the lowest exposure group, to maximize exposure contrast. Results The results of the search strategy are summarized in the PRISMA diagram (Fig. 1). After de-duplication, 9115 citations were screened, 1245 papers were retrieved, and 257 studies met all inclusion criteria. The year of publication of the 257 studies included ranged from 1978 to 2025. Most studies were conducted in Europe or North America (68%). In total there were 183 (71%) cross-sectional studies, 11 (4.3%) case-control studies, 41 (16%) cohort studies and 22 (8.6%) repeated cross-sectional studies. Using the NHLBI quality assessment tool, 15 (5.8%) studies were assessed to be good quality, 185 (72%) fair quality and 57 (22%) poor quality (Supplementary Table S1). By outcome of interest, 111 (41%) of the 257 studies reported on an acceptable COPD case definition, 147 (58%) reported on chronic bronchitis. Of these, 178 studies reported a risk estimate and were considered for inclusion in the meta-analyses. Fig. 1PRISMA diagram summarizing search results for the systematic review PRISMA diagram summarizing search results for the systematic review Administrative data Three studies used administrative data to ascertain cases of COPD, CB or emphysema in relation to typical workplace VGDF exposure. When combined, the resulting meta effect estimate (smoking adjusted) was 1.38 (0.90–2.11) with substantial heterogeneity (Table 1; Figure S1). In leave-one-out analyses, removal of Blanc et al. (2009) [39] resulted in a model with only two contributing estimates, but notably lowered the meta effect estimate to 1.09 (1.06–1.12). Table 1Summary results from meta effect analyses (mEE) for COPD, chronic bronchitis and emphysema that included adjustment for smoking. Dark grey cells are relationships for which there were insufficient studies meeting inclusion criteria to undertake meta-analyses Table 1Summary results from meta effect analyses (mEE) for COPD, chronic bronchitis and emphysema that included adjustment for smoking. Dark grey cells are relationships for which there were insufficient studies meeting inclusion criteria to undertake meta-analyses Summary results from meta effect analyses (mEE) for COPD, chronic bronchitis and emphysema that included adjustment for smoking. Dark grey cells are relationships for which there were insufficient studies meeting inclusion criteria to undertake meta-analyses COPD, diagnostic testing Twenty studies examined COPD (by diagnostic testing) in relation to VGDF exposure (n = 20; mEE = 1.51, 95%CI 1.31–1.73) (Fig. 2). All but two studies were cross-sectional in nature; all but two were published in 2010 or later. In the leave-one-out analysis, results were consistent except for the model where Sumit et al., (2020) [40] was removed. In this case the mEE was slightly lowered to 1.39 (95%CI 1.27–1.53) and heterogeneity was improved. In studies where exposure was considered in a more quantitative manner, results were similarly increased for the highest exposure group (mEE 1.46; 95%CI 0.60–3.55; I2 86%; Fig. S3) and the longest exposure duration group (mEE 1.45; 95%CI 0.94–2.21; I2 31%; Fig. S2) but differences did not reach statistical significance in either case. Models investigating smokers alone (n = 4; mEE 2.69, 95%CI 1.31–5.53) and non-smokers (n = 7; mEE 3.32, 95%CI 1.49–7.41) showed strong and statistically significant associations between occupational exposure and COPD (Fig. S4 and S5). Fig. 2Forest plot for meta-analysis examining COPD (by diagnostic testing) associated with occupational exposure, based on dichotomous exposure assessment [13, 14, 27, 40, 45–60] Forest plot for meta-analysis examining COPD (by diagnostic testing) associated with occupational exposure, based on dichotomous exposure assessment [13, 14, 27, 40, 45–60] COPD, self reported doctor diagnosed Fourteen studies contributed to a model for COPD (self-reported) and VGDF exposure (yes/no) (mEE = 1.48, 95%CI 1.23–1.77) (Fig. 3). A stronger relationship was seen among cross-sectional studies (n = 8; mEE = 1.84, 95%CI 1.57–2.15) (Fig. S6) with moderate heterogeneity as compared to longitudinal studies (cohort and repeated cross-sectional studies combined, n = 6) where mEE = 1.16 (95%CI 1.01–1.33) (Fig. S7). Self-reported COPD was more strongly associated with higher levels of exposure (n = 8; mEE = 1.94, 95%CI 1.49–2.53) (Fig. S8) as compared to longer durations of exposure (n = 5; mEE = 1.49, 95%CI 1.26–1.76) (Fig. S9).Fig. 3Forest plot for meta-analysis examining COPD (by self-report) associated with occupational exposure, based on dichotomous exposure assessment [61–74] Forest plot for meta-analysis examining COPD (by self-report) associated with occupational exposure, based on dichotomous exposure assessment [61–74] Chronic bronchitis Symptom based chronic bronchitis had the most studies available for meta-analysis (n = 29) and results were similar to those for COPD (mEE = 1.83, 95%CI 1.51–2.21) (Fig. 4). These studies were largely cross-sectional in nature (n = 23) with an additional six cohort or repeated cross-sectional designs published from 1990 to 2023. Fig. 4Forest plot for meta-analysis examining CHRONIC BRONCHITIS (by symptom report) associated with occupational exposure, based on dichotomous exposure assessment [75–98]. A restricted model with only “Fair” and “Good” quality studies yields an mEE 1.89, 95%CI 1.48–2.40 with substantial heterogeneity (I2 = 89.3%) Forest plot for meta-analysis examining CHRONIC BRONCHITIS (by symptom report) associated with occupational exposure, based on dichotomous exposure assessment [75–98]. A restricted model with only “Fair” and “Good” quality studies yields an mEE 1.89, 95%CI 1.48–2.40 with substantial heterogeneity (I2 = 89.3%) A stronger relationship was again seen among cross-sectional studies (n = 23; mEE = 1.92, 95%CI 1.63–2.26) (Fig. S10) as compared to longitudinal studies (cohort and repeated cross-sectional studies combined (n = 6; mEE = 1.31, 95%CI 0.81–2.14) (Fig. S11). The strength of the association was similar for those with longer durations of exposures (n = 12; mEE = 1.87, 95%CI 1.65–2.12) (Fig. S13). Those with higher levels of exposure had slightly stronger association with CB (n = 13; mEE = 1.97, 95% CI 1.46–2.66) (Fig. S12). The association between VGDF and CB was statistically significant for both smokers (n = 5; mEE = 1.29, 95%CI 1.08–1.55) (Fig. S14) and non-smokers (n = 12; mEE = 1.58, 95%CI 1.24–2.02) (Fig. S15). The interaction between smoking and occupational exposure could only be examined for chronic bronchitis. Four studies contributed a model that suggested an approximate doubling of risk associated with smoking (mEE = 2.17; 95%CI 1.62–2.91) and occupational exposure (mEE = 2.24; 95%CI 1.32–3.81) individually, and a meta effect estimate for combined smoking and occupational exposure that was approximately additive (mEE = 4.25, 95%CI 2.43–7.41) (Table 1 and Fig. S17). Emphysema There were few studies examining emphysema as a health outcome in relation to workplace VGDF exposures. Three studies examined self-reported doctor diagnosed emphysema, all adjusted for smoking (mEE = 1.13, 95%CI 0.50–2.57) (Table 1; Fig. S16). There were additional studies of emphysema that met the inclusion criteria, but many had not adjusted for smoking and therefore are not included in the model. Vapours, gases, dusts fumes Individual VGDF exposures were also examined, specifically dust (unspecified), organic dust, mineral dust and “gases, vapours or fumes” (Table 2) rather than specific individual exposures. These results suggested increased risk of COPD and chronic bronchitis associated with exposure, with stronger relationships observed for CB compared with COPD. One exception was mineral dusts where mEE were lower and did not reach statistical significance. Individual model results are shown in the Supplementary Material (Fig. S18-S30). Table 2Summary results from meta-analyses of exposure groups and both COPD and chronic bronchitisExposure GroupCOPD, by diagnostic testingCOPD, self-reported or diagnosed within studyChronic Bronchitis, by symptoms or diagnosed within studyDust, unspecifiedmEE = 1.40 (1.20–1.64);I2 = 48.1%,N = 12mEE = 2.05 (1.69–2.48);I2 = 0%,N = 3mEE = 1.70 (1.45–1.99);I2 = 60%,N = 17Biological and organic dustsmEE = 1.35 (1.18–1.55);I2 = 0%,N = 8mEE = 2.09 (0.98–4.46);I2 = 87.4%,N = 5Mineral and inorganic dustsmEE = 1.14 (0.99–1.32);I2 = 0%,N = 8mEE = 1.38 (0.80–2.39);I2 = 81.5%,N = 3Gases, vapours, and fumesmEE = 1.29 (1.11–1.49);I2 = 40.9%,N = 10mEE = 2.07 (1.71–2.51);I2 = 0%,N = 3mEE = 1.59 (1.21–2.08);I2 = 75.1%,N = 11PesticidesmEE = 1.72 (1.19–2.48);I2 = 0%,N = 4mEE = 1.60 (1.04–2.46);I2 = 67.1%,N = 3 Table 2Summary results from meta-analyses of exposure groups and both COPD and chronic bronchitisExposure GroupCOPD, by diagnostic testingCOPD, self-reported or diagnosed within studyChronic Bronchitis, by symptoms or diagnosed within studyDust, unspecifiedmEE = 1.40 (1.20–1.64);I2 = 48.1%,N = 12mEE = 2.05 (1.69–2.48);I2 = 0%,N = 3mEE = 1.70 (1.45–1.99);I2 = 60%,N = 17Biological and organic dustsmEE = 1.35 (1.18–1.55);I2 = 0%,N = 8mEE = 2.09 (0.98–4.46);I2 = 87.4%,N = 5Mineral and inorganic dustsmEE = 1.14 (0.99–1.32);I2 = 0%,N = 8mEE = 1.38 (0.80–2.39);I2 = 81.5%,N = 3Gases, vapours, and fumesmEE = 1.29 (1.11–1.49);I2 = 40.9%,N = 10mEE = 2.07 (1.71–2.51);I2 = 0%,N = 3mEE = 1.59 (1.21–2.08);I2 = 75.1%,N = 11PesticidesmEE = 1.72 (1.19–2.48);I2 = 0%,N = 4mEE = 1.60 (1.04–2.46);I2 = 67.1%,N = 3 Summary results from meta-analyses of exposure groups and both COPD and chronic bronchitis mEE = 1.40 (1.20–1.64); I2 = 48.1%, N = 12 mEE = 2.05 (1.69–2.48); I2 = 0%, N = 3 mEE = 1.70 (1.45–1.99); I2 = 60%, N = 17 mEE = 1.35 (1.18–1.55); I2 = 0%, N = 8 mEE = 2.09 (0.98–4.46); I2 = 87.4%, N = 5 mEE = 1.14 (0.99–1.32); I2 = 0%, N = 8 mEE = 1.38 (0.80–2.39); I2 = 81.5%, N = 3 mEE = 1.29 (1.11–1.49); I2 = 40.9%, N = 10 mEE = 2.07 (1.71–2.51); I2 = 0%, N = 3 mEE = 1.59 (1.21–2.08); I2 = 75.1%, N = 11 mEE = 1.72 (1.19–2.48); I2 = 0%, N = 4 mEE = 1.60 (1.04–2.46); I2 = 67.1%, N = 3 Sex Results from sex stratified models supported consistent association between VGDF and both COPD (diagnostic testing) and CB (Fig. S31-S34) for both men (COPD: mEE = 1.51 (95%CI 1.14–1.99); CB: mEE = 2.13 (95%CI 1.67–2.73)) and women (COPD: mEE = 1.68 (95%CI 1.38–2.05); CB: mEE = 1.97 (95%CI 1.44–2.70)). Discussion We report results of a systematic review and meta-analysis examining the relationship between workplace VGDF exposure and both COPD and chronic bronchitis. Summary results show a consistent relationship between workplace exposure and both COPD and chronic bronchitis. This relationship was present in both smokers and non-smokers, though slightly stronger in non-smokers, as previously reported [16, 17]. In sex-stratified models, the risk of COPD in relation to workplace exposures was weaker, but still statistically significant, among women. In models examining intensity (or level) of exposure and duration of exposure results showed stronger associations for the highest level of exposure, but less clear effects for the longest duration of exposure. Studies of CB presented the largest number of studies for analysis, most relying on a validated symptom-based definition of CB. Relatively few included studies used administrative data to ascertain COPD cases. The inclusion criteria required that a study based on administrative data use only International Classification of Disease (ICD) codes specific to the outcomes of interest. Studies where generic or unspecified codes were included in the case definition (e.g., ICD-9 490 bronchitis, not specified as acute or chronic) were excluded, since they could have included acute, transient, episodes of infective or irritant bronchitis, and this exclusion likely contributed to the smaller number of studies using administrative data among included studies. Based on the most stringent available diagnostic criteria of post-bronchodilator FEV1, the meta-analysis of 20 studies confirms a statistically significant increased risk of COPD from work exposures to VGDF (mEE = 1.51, 95%CI 1.31–1.73). A stronger relationship was observed with CB, based on symptoms or self-reported doctor-diagnosis (mEE = 1.83, 95%CI 1.83–2.21). When narrower (but still diverse) exposure groups were examined, effect estimates were statistically significant for objectively diagnosed COPD in studies of unspecified dusts (mEE = 1.40, 95% CI 1.20–1.64) and organic dusts (mEE = 1.35, 95%CI 1.18–1.55) but not for mineral dusts (mEE = 1.14, 95% CI 0.99–1.32). Results also reached statistical significance for exposure to gases, vapors or fumes (as a single exposure group). There were strong associations observed between occupational dust exposure and both COPD and chronic bronchitis. A slightly stronger effect was observed for dust (non-specific) and biological dusts than was observed for mineral dusts (Table 2), which is consistent with findings from a previous review by Sadhra et al. [18] Many specific exposures could not be fully examined in this systematic review and meta-analysis due to differences in outcome and exposure definitions that made combining of results from different studies challenging. Results from meta-analyses that examined the highest level of exposure (relative to the lowest level of exposure) and longest duration (relative to shortest duration) suggest that the associations with both COPD (by diagnostic testing and self-report) and chronic bronchitis are stronger among those with higher levels of exposure. The association was less strong but still statistically significant for longer durations of exposure. Potentially results may be underestimated due to a healthy worker survivor population in those studies. These findings suggest there may be an underlying exposure-response relationship, but this would be better assessed for individual exposures among studies with quantitative exposure information. Results show a consistent relationship between exposure and COPD in both smokers and non-smokers, evidence that COPD associated with workplace VGDF exposure occurs regardless of smoking status. The stronger association among non-smokers was not surprising as the baseline risk of COPD among un-exposed smokers (the reference group in the smoking model) is higher than the baseline risk of COPD among unexposed non-smokers. Blanc et al. (2009) [39] have reported on the combined effect of smoking and VGDF in models that examine COPD among three groups (nonsmokers with VGDF exposure, smokers without VGDF exposure, and smokers with VGDF exposures) relative to non-smokers without VGDF exposures. Results from Blanc et al. (2009) [39] suggested that that the risk of COPD from VGDF may be more than additive in smokers. Results from individual studies of COPD (with differing outcome definitions) within this review support this finding (Ma et al.; Mazitova et al. [41, 42]) but there were not enough sufficiently similar studies to conduct meta-analysis of the combined effect of smoking and occupational exposures on COPD. However, for CB, where there were sufficient studies to examine the combined effect, meta-analyses suggest that the combined effect of smoking and occupational exposure is approximately additive (Fig. S14, Table 3). Table 3Meta effect estimates for Chronic Bronchitis (by symptoms) among studies examining the combined effect of smoking and occupational exposures (yes/no)No smoking, no occupational exposureSmokingOccupational ExposuremEE (95%CI)I2NoNoneRef.-No smoking, with occupational exposureNoYes2.24 (1.32–3.81)45.30%Smoking history, no occupational exposureYesNone2.17 (1.62–2.91)0%Smoking history and occupational exposureYesYes4.25 (2.43–7.41)56.20% Table 3Meta effect estimates for Chronic Bronchitis (by symptoms) among studies examining the combined effect of smoking and occupational exposures (yes/no)No smoking, no occupational exposureSmokingOccupational ExposuremEE (95%CI)I2NoNoneRef.-No smoking, with occupational exposureNoYes2.24 (1.32–3.81)45.30%Smoking history, no occupational exposureYesNone2.17 (1.62–2.91)0%Smoking history and occupational exposureYesYes4.25 (2.43–7.41)56.20% Meta effect estimates for Chronic Bronchitis (by symptoms) among studies examining the combined effect of smoking and occupational exposures (yes/no) Strengths and limitations There are several limitations to this systematic review with meta-analysis. The review was limited to studies published in English and Chinese languages. Though a thorough grey literature search was conducted, only a small number (n = 4) of results from these sources met the inclusion criteria. The requirement of a minimum number of 15 cases for analyses likely resulted in the exclusion of studies from relatively small workplaces and less common (or emerging) exposure circumstances. The inclusion criteria focused on COPD and associated diagnoses with validated definitions of COPD, and chronic bronchitis. This study did not consider overlapping diagnoses, though the outcomes are not mutually exclusive. For inclusion as COPD, our criteria required a determination of COPD status (yes/no) thus studies of lung function or lung function decline as the outcome of interest, without a determination of COPD status were not captured in the search results or, if captured, did not meet the inclusion criteria. Additionally, studies of COPD severity were not included though it has been reported that COPD patients with occupational exposure may have more severe disease [15]. COPD determined by diagnostic testing did require the examination of post-bronchodilator spirometry, to align with clinical guidelines, increase confidence in the in diagnosis of COPD, and exclude asthma cases from the analysis [43]. This did result in the exclusion of many studies where pre and post bronchodilator testing was not completed. It also likely led to the disproportionate exclusion of workplace-based studies where bronchodilators may not have been administered for safety and ethical reasons. In addition, use of these diagnostic criteria likely excluded older studies, that also may have been associated with higher exposure levels. This may explain the lack of significant findings for mineral dusts in this review. The included studies had diverse exposure assessment approaches, which was a challenge when identifying studies that were sufficiently similar for combining in meta-analysis models. The multiple outcome groups as well as exposure assessment approaches resulted in relatively small numbers of studies suitable for combining in meta-analysis models, despite the large number of studies that met the inclusion criteria. In a previous review, Omland et al. (2014) undertook a systematic review of occupational COPD as part of the development of scientific guidance for the Danish National Board of Industrial Injuries and the Occupational Diseases Committee on Occupational COPD [24]. Omland et al. (2014) included studies that reported on spirometry defined COPD, including 68 studies in their qualitative analysis [24]. The authors felt that the included studies were “heterogeneous with regard to exposures and populations” and that this “heterogeneity precluded a formal meta-analysis.” Instead, they reported a qualitative synthesis and summary of the included studies concluding that there was a “consistent association between occupational exposures and COPD” [24]. Our findings are consistent with Omland et al. (2014) and have the added benefit of quantitative estimates of effect from meta-analyses [24]. The challenge of relatively high heterogeneity observed in meta regression models presented here is common when examining occupational epidemiology [44]. Occupational studies have significant variability in study population, exposure level and, in the case of VGDF, the specific exposure differed between studies. This could be potentially improved through the narrowing of research questions, focusing on specific exposures and/or industries, and limiting to specific time periods or geographic regions, though this presents a trade-off as any of these options would reduce the number of contributing studies. Conclusions & implications As previously recognised, our results support that occupational exposure to VGDF is a risk factor for development of COPD and CB. Workplace VGDF exposures make a significant and important contribution to the development of COPD and CB and should be routinely considered in clinical practice. Additional research is needed to better understand latency and minimum exposure level (or duration) associated with occupational COPD and CB in relation to individual exposures. Estimates from systematic reviews with meta-analyses can be used to refine estimates of the population attributable fraction and other measures of the burden of disease resulting from occupational exposure to VGDF. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1